Posted by Michael Wonder on 31 Dec 2021
FDA accepts Arcutis Biotherapeutics’ new drug application for roflumilast cream for adults and adolescents with plaque psoriasis
22 December 2021 - FDA has set a target action date of 29 July 2022.
Arcutis Biotherapeutics today announced the U.S. FDA's acceptance for review of the company’s new drug application for roflumilast cream for the treatment of psoriasis in adults and adolescents.
